재택 주입 요법 시장 보고서 : 제품별, 용도별, 지역별(2026-2034년)

The global home infusion therapy market size reached USD 47.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 72.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.65% during 2026-2034. The growing elderly population, along with the increasing preference for home healthcare, is propelling the market.

HOME INFUSION THERAPY MARKET ANALYSIS:

• Major Market Drivers: Rising advancements in medical technology are making at-home infusions safer and more efficient, which is propelling the market.
• Key Market Trends: The increasing number of chronic disease cases is advancing the need for cost-effective home treatments, thereby acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the major market companies include B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Eli Lilly and Company, Fresenius SE & Co. KGaA, ICU Medical Inc., JMS Co. Ltd., Nipro Corporation, Option Care Health Inc. (Walgreen Co.), Smiths Group plc, and Terumo Corporation, among many others.
• Geographical Trends: North America exhibits a clear dominance in the market due to strong reimbursement systems and increasing prevalence of chronic diseases, thereby fostering higher demand for convenient at-home treatment solutions across the region.
• Challenges and Opportunities: Inconsistent patient safety and the need for proper administration are hindering the market. However, enhancing training for caregivers and integrating advanced monitoring technologies for real-time oversight of infusion treatments will continue to strengthen the market over the forecast period.

HOME INFUSION THERAPY MARKET TRENDS:

Increasing Adoption of Advanced Infusion Technology

Technological advancements are enhancing home infusion therapy by introducing smart infusion pumps and safety software that improve precision, safety, and efficiency. In contrast, these innovations help to reduce medication errors, offer better monitoring, and provide seamless integration with digital systems, thereby streamlining home-based care for patients and reducing the burden on caregivers. For instance, in April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ Safety Software, thereby enhancing home infusion therapy by offering integrated smart pump solutions. This development boosts patient safety and efficiency, addressing clinician workload challenges and advancing connected care.

Growing Demand for Specialized Infusion Services

The need for specialized infusion services has grown as more patients require complex treatments for chronic conditions. In addition, these services provide tailored therapies delivered in a home setting, thereby reducing the need for hospital visits. Furthermore, this personalized approach helps to manage long-term illnesses effectively while improving patient comfort and treatment outcomes. For instance, in February 2024, Dynamic Access launched dynamic infusion, a specialty home infusion nursing provider, which is serving patients with chronic conditions like autoimmune disorders and multiple sclerosis. Also, they partnered with 35+ specialty pharmacies, offering over 10,000 home visits annually across nine states, enhancing patient care.

Integration of Digital Health Tools

The integration of digital tools in home infusion therapy is enabling better patient monitoring and real-time data sharing between healthcare providers and patients. Moreover, these systems enhance remote care management by offering insights into therapy progress, thereby improving adherence and facilitating adjustments to treatment plans while minimizing the need for in-person consultations. For instance, in May 2024, Moog received U.S. FDA clearance for the CURLIN 8000 ambulatory infusion system, designed specifically for home infusion therapy. This system offers precise multi-therapy infusions and intuitive user interfaces and integrates with CURLIN RxManager, enhancing safety and control for home care pharmacists and patients.

GLOBAL HOME INFUSION THERAPY INDUSTRY SEGMENTATION:

Breakup by Product:

• Infusion Pumps
  • Elastomeric
  • Electromechanical
  • Gravity
  • Others
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

In fusion pumps currently hold the largest home infusion therapy market demand

Infusion pumps exhibit a clear dominance in the market due to their precision in medication delivery, as they offer defined medication delivery and enhancing patient care. For example, Baxter launched its advanced Spectrum IQ pump, thereby improving patient safety and remote monitoring capabilities for home-based care.

Breakup by Application:

• Anti-Infective
• Endocrinology
  • Diabetes
  • Others
• Hydration Therapy
  • Athletes
  • Others
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals

Anti-infectives currently hold the largest home infusion therapy market statistics

Anti-infectives lead the market due to their increased use in treating severe infections, such as pneumonia, with intravenous antibiotics. For instance, Smiths Medical's CADD infusion system facilitates precise delivery and supports increased adoption.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the infusion therapy market revenue

The home infusion therapy market outlook has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the home infusion therapy market overview, North America dominates the market, which is driven by advanced healthcare infrastructure and increasing demand for home-based treatments. Moreover, the region benefits from a growing elderly population and rising chronic disease cases, prompting more home infusion therapies. For example, CVS Health expanded its home infusion services, thereby enhancing access to these treatments across the U.S. Furthermore, high demand for at-home care, alongside supportive reimbursement policies and technological advancements, further strengthens the region's dominance in this market.

COMPETITIVE LANDSCAPE:

The home infusion therapy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all market home infusion therapy companies have also been provided. Some of the key players in the market include:

• B. Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Company
• Eli Lilly and Company
• Fresenius SE & Co. KGaA
• ICU Medical Inc.
• JMS Co. Ltd.
• Nipro Corporation
• Option Care Health Inc. (Walgreen Co.)
• Smiths Group plc
• Terumo Corporation

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global home infusion therapy market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global home infusion therapy market?
• What is the impact of each driver, restraint, and opportunity on the global home infusion therapy market growth?
• What are the key regional markets?
• Which countries represent the most attractive home infusion therapy market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the home infusion therapy market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the home infusion therapy market?
• What is the competitive structure of the global home infusion therapy market?
• Who are the key players/companies in the global home infusion therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Home Infusion Therapy Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Infusion Pumps
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Elastomeric
    • 6.1.2.2 Electromechanical
    • 6.1.2.3 Gravity
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Intravenous Sets
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 IV Cannulas
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Needleless Connectors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Anti-Infective
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Endocrinology
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Diabetes
    • 7.2.2.2 Others
  • 7.2.3 Market Forecast
• 7.3 Hydration Therapy
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Athletes
    • 7.3.2.2 Others
  • 7.3.3 Market Forecast
• 7.4 Chemotherapy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Enteral Nutrition
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Parenteral Nutrition
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Specialty Pharmaceuticals
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Others
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 B. Braun Melsungen AG
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Baxter International Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Becton Dickinson and Company
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Eli Lilly and Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Fresenius SE & Co. KGaA
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 ICU Medical Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 JMS Co. Ltd.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
  • 13.3.8 Nipro Corporation
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Option Care Health Inc. (Walgreen Co.)
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Smiths Group plc
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Terumo Corporation
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis